MannKind reports PK/PD data supporting Furoscix ReadyFlow IV-equivalent exposure
MannKind said new PK/PD data presented at HFSA 2026 showed Furoscix ReadyFlow’s subcutaneous injection achieved IV-equivalent exposure and a diuretic effect.
MannKind said new PK/PD data presented at HFSA 2026 showed Furoscix ReadyFlow’s subcutaneous injection achieved IV-equivalent exposure and a diuretic effect.